Bruker Corporation $BRKR Stock Position Cut by Invesco Ltd.

Key Points

• Invesco Ltd. has decreased its stake in Bruker Corporation by 22.4%, now holding approximately 213,231 shares valued at about $8.9 million.
• Bruker Corporation's CEO Frank H. Laukien purchased 2,608 shares for approximately $100,042, increasing his total ownership to about 38.46 million shares.
• Analysts have lowered price targets for Bruker, with the average target now at $51.30 after several firms issued "neutral" and "overweight" ratings.

Invesco Ltd. cut its stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) by 22.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 213,231 shares of the medical research company's stock after selling 61,607 shares during the period. Invesco Ltd. owned about 0.14% of Bruker worth $8,900,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. CGN Advisors LLC lifted its stake in Bruker by 1.4% in the first quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company's stock worth $919,000 after purchasing an additional 296 shares during the last quarter. New York State Teachers Retirement System lifted its stake in shares of Bruker by 0.8% during the first quarter. New York State Teachers Retirement System now owns 37,115 shares of the medical research company's stock worth $1,549,000 after buying an additional 300 shares during the period. State of Michigan Retirement System lifted its position in Bruker by 1.1% during the first quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company's stock valued at $1,106,000 after purchasing an additional 300 shares during the period. Louisiana State Employees Retirement System lifted its position in Bruker by 1.0% during the first quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the medical research company's stock valued at $1,294,000 after purchasing an additional 300 shares during the period. Finally, KBC Group NV increased its holdings in Bruker by 0.8% in the first quarter. KBC Group NV now owns 44,715 shares of the medical research company's stock valued at $1,866,000 after buying an additional 349 shares in the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BRKR. The Goldman Sachs Group dropped their price objective on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the company a "hold" rating in a research note on Tuesday, August 5th. Barclays dropped their price objective on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Monday, August 4th. Bank of America dropped their price target on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Finally, Citigroup dropped their price target on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Bruker currently has a consensus rating of "Hold" and an average target price of $51.30.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien acquired 2,608 shares of the firm's stock in a transaction on Friday, June 6th. The stock was bought at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the purchase, the chief executive officer directly owned 38,462,171 shares in the company, valued at $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 27.30% of the stock is currently owned by corporate insiders.

Bruker Price Performance

Shares of NASDAQ BRKR traded up $0.32 during midday trading on Friday, hitting $33.78. The company had a trading volume of 945,614 shares, compared to its average volume of 2,438,284. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $5.13 billion, a price-to-earnings ratio of 64.96, a price-to-earnings-growth ratio of 2.78 and a beta of 1.16. The business has a 50-day simple moving average of $38.12 and a two-hundred day simple moving average of $40.46. Bruker Corporation has a twelve month low of $30.00 and a twelve month high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $797.40 million during the quarter, compared to analyst estimates of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business's quarterly revenue was down .4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Equities research analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.6%. The ex-dividend date is Tuesday, September 23rd. Bruker's payout ratio is currently 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.